© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Arcus Biosciences, Inc. (RCUS) shows an Average True Range (ATR) of 1.31 and an Enterprise Value of 1.29B. Its average trading volume over the past 3 months is 1.77M, indicating liquidity. These fundamental metrics provide insight into RCUS's underlying financial health and market activity.
Arcus Biosciences, Inc. (RCUS) technical indicators as of December 23, 2025: the SMA 20 is -3.95%, SMA 50 at 10.26%, and SMA 200 at 85.4%. The RSI 14 value is 53.77, suggesting its current momentum. These technical analysis signals help assess RCUS's price trends and potential future movements.
Arcus Biosciences, Inc. (RCUS) stock performance overview as of December 23, 2025: The 52-week high is $26.4 (currently -12.05% below), and the 52-week low is $6.5 (currently 257.23% above). Over the past year, RCUS's performance is 40.64%, compared to the S&P 500's 12.87% change.
According to market data, Arcus Biosciences, Inc. (RCUS) stock's recent performance metrics show that over the last month, RCUS is 14.84%, with a Year-to-Date (YTD) performance of 55.94%. Over the past year, the stock has seen a 40.64% change. These figures summarize RCUS's price movements across various periods, reflecting its historical returns.
According to current financial data, RCUS stock's P/E (TTM) ratio is -7.02, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for RCUS, including P/S (10.35), P/B (5.62), and P/FCF (-5.35), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.